Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084329 | 0.88 | FAAH (0.51) | FAAHHCRTR1HCRTR2KDM1AMCHR1 | |
| SCHEMBL15081965 | 0.81 | OPRM1 (0.53) | FAAHOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL15084309 | 0.76 | HRH3 (0.48) | FAAHMCHR1 | |
| SCHEMBL14375252 | 0.75 | ACHE (0.55) | FAAHKDM1AMCHR1 | |
| SCHEMBL807185 | 0.72 | FAAH (0.43) | FAAHOPRM1OPRD1OPRK1HCRTR1 | |
| SCHEMBL807181 | 0.71 | DPP4 (0.47) | FAAHHCRTR1HCRTR2 | |
| SCHEMBL15081988 | 0.70 | KDM4E (0.57) | — | |
| SCHEMBL15082011 | 0.70 | ALDH1A1 (0.45) | — | |
| SCHEMBL806905 | 0.70 | ALDH1A1 (0.45) | — | |
| SCHEMBL807593 | 0.70 | FAAH (0.57) | FAAHOPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | FAAH 4421/4885OPRM1 3387/4885OPRD1 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.